- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.10. | hVIVO PLC - Long Term Incentive Plan/ PDMR Notification | - | RNS | ||
| 07.10. | hVIVO upbeat on positive human challenge trial results with client | 1 | Sharecast | ||
| 07.10. | hVIVO PLC - Positive results from RSV human challenge trial | - | RNS | ||
| 30.09. | hVIVO gets HSE clearance, launches new lab services | 2 | Sharecast | ||
| 30.09. | hVIVO PLC - Launch of full suite of hLAB standalone services | - | RNS | ||
| 10.09. | hVIVO hails "record" half-year revenue, as profit soars 70% higher | 2 | Alliance News | ||
| 10.09. | Clinical trial specialist hVivo's H1 revenues jump by 30% | 1 | RTE.ie | ||
| 10.09. | hVIVO PLC - Interim results | - | RNS | ||
| 20.08. | hVIVO PLC - Notice of results | 2 | RNS | ||
| 05.08. | JD Wetherspoon chair offloads 1% stake while hVIVO chair exits the register | Directors Deals | 1 | Shares | ||
| 05.08. | Life sciences firm hVIVO cancels Euronext listing to focus on London | 1 | City A.M. | ||
| 05.08. | Three Quick Facts: UK Oil & Gas, Clarkson, hVIVO | 1 | The Armchair Trader | ||
| 05.08. | hVIVO PLC - Euronext cancellation | - | RNS | ||
| 23.07. | hVIVO PLC - Director/PDMR Shareholding | - | RNS | ||
| 17.07. | hVivo expects half year revenues to rise by 30% | 1 | RTE.ie | ||
| 17.07. | hVIVO reports 31% revenue jump; relocation to improve efficiencies | 1 | Alliance News | ||
| 17.07. | Hvivo delivers record revenues in H1, reiterates FY guidance | 1 | Sharecast | ||
| 17.07. | hVIVO PLC - Trading update | - | RNS | ||
| 02.07. | hVIVO secures biggest field study contract to date | 2 | Sharecast | ||
| 02.07. | hVIVO PLC - Change of registered address | - | RNS |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PLUS THERAPEUTICS | 1,204 | -2,75 % | Plus Therapeutics granted extension by Nasdaq | ||
| SPINEWAY | 0,126 | -8,39 % | Spineway: Continued organic growth - Nine-month 2024 revenue of €9.1 million (+21%) | Press release Ecully, October 15, 2024 - 6 p.m. SPINEWAY Continued organic growthNine-month 2024 revenue of €9.1 million (+21%) In thousands of euros20242023Change %Q1 revenue3,0702,39828%Q2... ► Artikel lesen | |
| ASENSUS SURGICAL | 0,305 | 0,00 % | KARL STORZ akquiriert den US-amerikanischen Robotik-Spezialisten Asensus Surgical | Tuttlingen / Research Triangle Park, USA (ots) - Das familiengeführte und international agierende Medizintechnikunternehmen KARL STORZ gibt die Akquisition des innovativen Robotik-Spezialisten Asensus... ► Artikel lesen | |
| MEDIVOLVE | 0,003 | 0,00 % | Medivolve Inc (2): Medivolve president, CEO Preiner resigns | ||
| LIFEWARD | 2,410 | +7,11 % | Lifeward, Inc.: Lifeward Launches Direct Sales of AlterG Product Line in Germany | MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing... ► Artikel lesen | |
| JD HEALTH | 3,200 | +0,63 % | JD Health-Aktie kann Vortagsniveau nicht halten (3,32 €) | Im Minus liegt gegenwärtig der Anteilsschein von JD Health . Zuletzt zahlten Investoren für das Papier 3,32 Euro. Für die JD Health-Aktie steht gegenwärtig ein Verlust von 3,49 Prozent zu Buche. Die... ► Artikel lesen | |
| EKSO BIONICS | 0,866 | +6,39 % | H.C. Wainwright senkt Kursziel für Ekso Bionics um 10%, hält aber an Kaufempfehlung fest | ||
| IMUNON | 0,865 | -3,89 % | Imunon, Inc.: IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting | ||
| AVINGER | 0,784 | +0,45 % | Avinger, Inc.: Avinger to Announce Third Quarter 2024 Results on November 7, 2024 | REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system... ► Artikel lesen | |
| ROCKWELL MEDICAL | 3,632 | +1,68 % | RMTI Stock Rises 138% in Q3: What Should You Do Ahead of Earnings? | ||
| VIRIDIAN THERAPEUTICS | 20,600 | -1,90 % | Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results | WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare... ► Artikel lesen | |
| SINTX TECHNOLOGIES | 3,040 | 0,00 % | Sintx Technologies, Inc. - 8-K, Current Report | ||
| AETHLON MEDICAL | 0,356 | -2,20 % | Aethlon Medical, Inc.: Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update | Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies... ► Artikel lesen | |
| STAGEZERO LIFE SCIENCES | 0,028 | 0,00 % | StageZero Life Sciences Ltd: StageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials Under the Failure To File Cease Trade Order | TORONTO, ON / ACCESSWIRE / July 9, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA gene... ► Artikel lesen | |
| NEURONETICS | 1,028 | +8,44 % | Neuronetics extends Madryn registration rights period |
HVIVO PLC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +8,02 % bei einem Aktienkurs von 0,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HVIVO PLC finden Sie auf Wallstreet Online.
